Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Beigene Grants Share Options to Five Employees

12/03/2021 | 03:22am EST


ę MT Newswires 2021
All news about BEIGENE, LTD.
01/10BEIGENE : China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients..
PU
01/10BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
01/07BeiGene - China NMPA Approves Tislelizumab as Second or Third-Line Treatment for Patien..
AQ
01/06Chinese Regulators OK BeiGene's Non-Small Cell Lung Cancer Treatment
MT
01/06BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
BU
01/06Chinese Regulator Approves BeiGene's Tislelizumab as Second- or Third-Line Treatment fo..
MT
01/06China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with L..
BU
01/06BeiGene, Ltd. Announces China NMPA Approves Tislelizumab as Second- or Third-Line Treat..
CI
01/05Asian ADRs Move Higher in Wednesday Trading
MT
01/05China Mobile shares edge higher in Shanghai debut
RE
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 229 M - -
Net income 2021 -1 191 M - -
Net cash 2021 3 458 M - -
P/E ratio 2021 -21,0x
Yield 2021 -
Capitalization 24 519 M 24 519 M -
EV / Sales 2021 17,1x
EV / Sales 2022 15,2x
Nbr of Employees 7 600
Free-Float 67,7%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 238,64 $
Average target price 410,10 $
Spread / Average Target 71,8%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-11.92%24 519
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338